ResearcherBeaumont HealthNo recent work listed

John M. Robertson

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112266232. Sources: OpenAlex.

Their work

Papers: 5 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper

Papers 5

The significance of Trk receptors in pancreatic cancer. Co-author DOI 10.1177/1010428317692256 ↗
Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unres… Co-author DOI 10.1007/s12029-016-9821-9 ↗
Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.08.050 ↗
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenoc… First author DOI 10.1016/j.ijrobp.2011.09.022 ↗
Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. Last author DOI 10.1016/j.ijrobp.2012.01.008 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Andrew M Baschnagel · 2 shared papers, 2012–2017 · strength 0.09
- Paper The significance of Trk receptors in pancreatic cancer. DOI 10.1177/1010428317692256 ↗
- Paper Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. DOI 10.1016/j.ijrobp.2012.01.008 ↗
Jiayi Huang · 2 shared papers, 2012–2016 · strength 0.09
- Paper Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherap… DOI 10.1007/s12029-016-9821-9 ↗
- Paper Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherap… DOI 10.1016/j.ijrobp.2011.09.022 ↗
Matthew D. Johnson · 1 shared paper, 2017 · strength 0.06
- Paper The significance of Trk receptors in pancreatic cancer. DOI 10.1177/1010428317692256 ↗
George David Wilson · 1 shared paper, 2017 · strength 0.06
- Paper The significance of Trk receptors in pancreatic cancer. DOI 10.1177/1010428317692256 ↗
Sunpreet S. Rakhra · 1 shared paper, 2016 · strength 0.05
- Paper Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherap… DOI 10.1007/s12029-016-9821-9 ↗
William C. Small · 1 shared paper, 2016 · strength 0.05
- Paper Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherap… DOI 10.1007/s12029-016-9821-9 ↗
Mary F. Mulcahy · 1 shared paper, 2016 · strength 0.05
- Paper Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherap… DOI 10.1007/s12029-016-9821-9 ↗
John P. Hayes · 1 shared paper, 2016 · strength 0.05
- Paper Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherap… DOI 10.1007/s12029-016-9821-9 ↗
Di Yan · 1 shared paper, 2012 · strength 0.04
- Paper Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherap… DOI 10.1016/j.ijrobp.2011.09.022 ↗
Hong Ye · 1 shared paper, 2012 · strength 0.03
- Paper Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic c… DOI 10.1016/j.ijrobp.2010.08.050 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.